Cernevit Stungulyfsstofn, lausn Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

cernevit stungulyfsstofn, lausn

baxter medical ab* - vítamín a (palmítat); colecalciferolum inn; vítamín e (tocoferolum nfn); acidum ascorbicum inn; thiaminum cocarboxylase tetrahýdrat; riboflavinum natríumfosfat díhýdrat; pyridoxinum hýdróklóríð; cyanocobalaminum inn; acidum folicum inn; dexpanthenolum inn; biotinum inn; nicotinamidum inn - stungulyfsstofn, lausn

Uromitexan Stungulyf, lausn 100 mg/ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

uromitexan stungulyf, lausn 100 mg/ml

baxter medical ab* - mesnum inn - stungulyf, lausn - 100 mg/ml

Scopoderm Forðaplástur 1 mg/72 klst. Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

scopoderm forðaplástur 1 mg/72 klst.

baxter medical ab - scopolaminum - forðaplástur - 1 mg/72 klst.

Paracetamol Baxter Innrennslislyf, lausn 10 mg/ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

paracetamol baxter innrennslislyf, lausn 10 mg/ml

baxter holding b.v.* - paracetamolum inn - innrennslislyf, lausn - 10 mg/ml

Pemetrexed Baxter Evrópusambandið - íslenska - EMA (European Medicines Agency)

pemetrexed baxter

baxter holding b.v. - pemetrexed disodium heptahydrate - carcinoma, non-small-cell lung; mesothelioma - Æxlishemjandi lyf - malignant pleural mesotheliomapemetrexed baxter in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancerpemetrexed baxter in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5. pemetrexed baxter is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see section 5. pemetrexed baxter is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.

Plasmalyte Glucos 50 mg/ml Innrennslislyf, lausn 50 mg/ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

plasmalyte glucos 50 mg/ml innrennslislyf, lausn 50 mg/ml

baxter medical ab* - glucosum; natrii chloridum; kalii chloridum; magnesii chloridum; natrii acetas; natrii gluconas - innrennslislyf, lausn - 50 mg/ml

TISSEEL Lausnir fyrir vefjalím Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

tisseel lausnir fyrir vefjalím

baxter medical ab - human fibrinogen; human factor xiii; bovine aprotinin; human thrombin; calcii chloridum; thrombin; protein - lausnir fyrir vefjalím

Plasmalyte Innrennslislyf, lausn Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

plasmalyte innrennslislyf, lausn

baxter medical ab* - sodium chloride; kalii chloridum; magnesii chloridum; sodium acetate trihydrate; natrii gluconas - innrennslislyf, lausn

Holoxan Innrennslisstofn, lausn 500 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

holoxan innrennslisstofn, lausn 500 mg

baxter medical ab* - ifosfamidum inn - innrennslisstofn, lausn - 500 mg

Holoxan Innrennslisstofn, lausn 2000 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

holoxan innrennslisstofn, lausn 2000 mg

baxter medical ab* - ifosfamidum inn - innrennslisstofn, lausn - 2000 mg